Daratumumab resistance is frequent in advanced ‐stage multiple myeloma patients irrespective of CD38 expression and is related to dismal prognosis
European Journal of Haematology, EarlyView.
Source: European Journal of Haematology - Category: Hematology Source Type: research
More News: Myeloma